Coronary Drug Project (CDP): Looking Back 50 Years

David L DeMets, PhD **Emeritus - Univ of Wisconsin-Madison** Lawrence Friedman, MD Retired, NHLBI Janet Wittes, PhD **StatCollaborative** James Neaton, PhD **Univ of Minnesota**


CDP Contributions to RCTs

- CDP was a large multicenter trial, sponsored by NHLBI, to test cholesterol 5 lowering drugs on CV mortality compared to a placebo arm.
- Started in 1966, completed in 1974
- Recruited 8,341 patients with previous MI
- 3 of the 5 arms were terminated early for harm or no benefit
- One arm was completed with no benefit
- Another arm demonstrated a benefit

Long Term CDP Contributions


- While successful in evaluating 5 lipid lowering drugs, perhaps most important is that the CDP set the stage for future RCTs
- Organizational structure (L Friedman)
- Monitoring methods for accumulating data & terminating arms early (D DeMets)
- Appropriate methods of analysis (J Wittes)
- Impact on other NIH and industry sponsored trials (J Neaton)

CDP Pioneers: Jerry Stamler, MD Professor, Northwestern Univ





CDP Pioneers: Chris Klimt, MD Maryland Medical Research Institute



- Director of CDP Coordinating Center
- Founding Member of the SCT

Statistical Pioneers: Jerry Cornfield



- Senior
 biostatistician,
 National Heart
 Lung & Blood
 Institute
- Statistical consultant to the CDP

Statistical Pioneers: Max Halperin, PhD



- Senior
 biostatistician:
 National Heart,
 Lung & Blood
 Institute
- Statistical Consultant to the CDP




- Young Curt Meinert at work –
- PhD, 1964
 Univ of
 Minnesota
- Founder of SCT & Journal CCT




- Curt Meinert again
- This isn't Sleepy Eye MN anymore




- A young Paul Canner at work on the CDP
- PhD, Univ of Minnesota, 1966



- Meinert a few (50+) years later
- Same old Curt



- Canner in his biostatistics retirement
- Still quiet and far too modest



ADoubleThreat

The Magnificent Seven (Required Reading)

- CDP: 1981 CCT, Decision Making in CTs
- CDP: 1970 JAMA, Termination of Hi dose Estrogen
- CDP: 1972 JAMA, Termination of Dextrothyroxin
- CDP: 1973 JAMA, Termination of Lo dose estrogen
- CDP: 1975 JAMA, Clofibrate & Niacin
- Canner: 1977 Biometrics, Monitoring long term trials
- CDP: 1980 NEJM, Influence of adherence & intermediate response on analysis

CDP Contributions to RCTs

- Organizational structure & termination of 3 arms (L Friedman)
- Methods for monitoring accumulating data & terminating arms early (D DeMets)
- "Inappropriate" methods of RCT analysis (J Wittes)
- Impact on other NIH and industry sponsored trials (J Neaton)